Focused On-demand Library for Probable ATP-dependent RNA helicase DHX37

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IY37

UPID:

DHX37_HUMAN

Alternative names:

DEAH box protein 37

Alternative UPACC:

Q8IY37; Q9BUI7; Q9P211

Background:

The Probable ATP-dependent RNA helicase DHX37, also known as DEAH box protein 37, is pivotal in ribosome biogenesis, specifically in the maturation of the small ribosomal subunit. It facilitates the release of the U3 snoRNP from pre-ribosomal particles and is a crucial component of the small subunit (SSU) processome. This protein's involvement extends to early testis development and is suggested to play a role in brain development.

Therapeutic significance:

Given its critical functions in ribosome biogenesis and potential involvement in brain and testis development, DHX37 presents as a promising target for therapeutic intervention in neurodevelopmental disorders and sex development disorders. Understanding the role of DHX37 could open doors to potential therapeutic strategies.